Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)

(2010) M. S. Rosati et al.   ANNALS OF ONCOLOGY

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) F. Cardoso et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Randomized Study of Taxane Versus TS-1 in Women with Metastatic or Recurrent Breast Cancer (SELECT BC)

(2010) H. Mukai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer

(2010) Hong-Bin Xu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Third consensus on medical treatment of metastatic breast cancer

(2009) S. Beslija et al.   ANNALS OF ONCOLOGY

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

(2009) E. D. Saad et al.   ANNALS OF ONCOLOGY

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

(2009) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

(2009) Fatima Cardoso et al.   JNCI-Journal of the National Cancer Institute

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

(2008) Tomasz Burzykowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

(2008) A. M. Brewster et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer

(2008) A. Ardavanis et al.   ONCOLOGIST